Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-06-28
2011-06-28
Pak, Michael (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07968301
ABSTRACT:
The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways.
REFERENCES:
patent: 5780263 (1998-07-01), Hastings et al.
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6489445 (2002-12-01), Brunkow et al.
patent: 6495736 (2002-12-01), Brunkow et al.
patent: 6803453 (2004-10-01), Brunkow et al.
patent: 6875570 (2005-04-01), Gerlach et al.
patent: 7381409 (2008-06-01), Winkler et al.
patent: 7578999 (2009-08-01), Winkler et al.
patent: 2004/0158045 (2004-08-01), Brunkow et al.
patent: 2005/0106683 (2005-05-01), Winkler et al.
patent: 2007/0072797 (2007-03-01), Robinson et al.
patent: 2007/0110747 (2007-05-01), Paszty et al.
patent: 2008/0160060 (2008-07-01), Ellies
patent: WO 00/32773 (2000-06-01), None
patent: WO 01/92308 (2001-12-01), None
patent: WO 02/24888 (2002-03-01), None
Albertsen et al., “A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21,” Nature Genetics, 7:472-479 (1994).
Balemans et al., “Localization of the Gene for Sclerosteosis to the van Buchem Disease-Gene Region on Chromosome 17q12-q21,” Am. J. Hum. Genet., 64:1661-1669 (1999).
Bradley et al., “Modifying the Mouse: Design and Desire,” Bio/Technology, 10:534-539 (1992).
Campbell et al., “Totipotency or Multipotentiality of Cultured Cells: Applications and Progress,” Theriogenology, 47:63-72 (1997).
Chan et al., “New paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists,” Current Opinion in Investigational Drugs, 8(4):293-298 (2007).
Cook et al., “Structural Basis for a Functional Antagonist in the Transforming Growth Factor β Superfamily,” J. Biol. Chem., 280(48):40177-186 (2005).
Hoffman et al., “BMP Signaling Pathways in Cartilage and Bone Formation,” Critical Review in Eukaryotic Gene Expression, 11(1-3):23-45 (2001).
Keller et al., “Molecular Recognition of BMP-2 and BMP Receptor IA,” Nat. Struct. Mol. Biol., 11(5):481-488 (2004).
Li et al., “Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signalling,” Jour. Bio. Chem., 280(20); 19883-19887 (2005).
Lian et al., “Bone Formation: Osteoblast Lineage Cells, Growth Factors, Matrix Proteins, and the Mineralization Process,” Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th Edition, 14-29 (1999).
Mullins et al., “Transgenesis in the Rat and Larger Mammals,” J. Clin. Invest. 97(7):1557-1560 (1996).
Oshima et al., “TGF-β Receptor Type II Deficiency ReSults in Defects of Yolk Sac Hematopoiesis and Vasculogenesis,” Developmental Biology 179:297-302 (1996).
Pittenger et al., “Multilineage Potential of Adult Human Mesenchymal Stem Cells,” Science 284:143-147 (1999).
Pockwinse et al., “Expression of Cell Growth and Bone Specific Genes at Single Cell Resolution During Development of Bone Tissue-Like Organization in Primary Osteoblast Cultures,” Journal of Cellular Biochemistry 49:310-323 (1992).
Schmitt et al., “Bone Morphogenetic Proteins: An Update on Basic Biology and Clinical Relevance,” Journal of Orthopaedic Research 17:269-278 (1999).
Smith, “TGF β inhibitors, new and unexpected requirements in vertebrate development,” TIG, 15(1):3-5 (1999).
Van Bezooijen et al., “Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone Formation,” J. Bone. Miner. Res. 22:19-28 (2007).
Non-Final Office Action mailed Sep. 17, 2009 in U.S. Appl. No. 11/508,701 (Paper No. 20090903).
Response to Non-Final Office Action mailed Sep. 17, 2009 in U.S. Appl. No. 11/508,701.
Capecchi, 1994, Scientific American, pp. 52-59.
Brunkow, et al., US 2003/0166247 A1.
Houdebine, 1994, J. Biotech, 34, pp. 269-287.
Wall, Theriogenology, 45:57-68, 1996.
Niemann, Transg. Res., 7:73-75, 1998.
Keri et al., PNAS, 97(1):383-38, 2000.
Brunkow et al., Am. J. Hum. Genet., 68:577-589, 2001.
Balmain et al., Trends in Genetics, 14(4):139-144, 1998.
Cameron, Molec. Biol., 7:253-265, 1997.
Aubin, J.E., et al., Monoclonal Antibodies as Tools for Studying the Osteoblast Lineage, Microscopy Research and Technique, 33:128-140 (1996).
Bachiller, D., et al., The organizer factors Chordin and Noggin are required for mouse forebrain development Nature, vol. 403 (Feb. 10, 2000).
Balemans, W., et al., Extracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators, Developmental Biology 250:231-250 (2002).
Balemans, W.. et al.. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST), Human Molecular Genetics, vol. 10 (5): 537-543 (2001).
Bork, P., The modular architecture of a new family of growth regulators related to connective tissue growth factor, FEBS Letters 327(4125-130 (Jul. 1993).
Boyden, L.M., et at, High Bone Density Due to a Mutation in LOL-Receptor-Related Protein 5, The New England Journal of Medicine. vol. 348(20). pp. 1513-1521 (May 16, 2002).
Bruder, S.P., et al., Monoclonal Antibodies Reactive With Human Osteogenic Cell Surface Antigens, Elsevier, Bone vol. 21, No. 3:225-235 (Sep. 1997).
Brunkow. M.E., et al, Bone Dysplasla Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot-Containing Protein, Am. J. Hum. Genet. 68:577-589 (2001).
Chen, X., et al.. Thy-1 Antigen Expression by Cells in the Osteoblast Lineage, Journal of Bone and Mineral Research, 14 (3): 362-375 (1999).
Dewitt, N., Bone and Cartilage, Nature 423:315 (May 2003).
Ellies, D.L., et al., Novel Wnt Inhibitor, WISE, Affects Bone Density (manuscript).
Gong, Y., et al., LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development. Cell 107: 513-523 (Nov. 16, 2001).
Hamersma, H., el at, The natural history of sclerosteosis, Clinical Genetics 63:192-197 (2003).
Harada, S., et al, Control of osteoblast function and regulation of bone mass, Nature 423:349-355 (2003).
Harris, S., et al. Human Fetal Osteoblast Progenitor Cell Lines (hFOB), http.//www.mayo.edutechcomm/93010.html, visited Jun. 11, 2003.
Hartley, K.O., et al., Targeted gene expression in trasngenicXenopususing the binary Ga14-UAS system, Proc. Natl. Acad. Sci. 99(3): 1377-1382, 2002.
Hartmann. C., Wnt-signaling and skeletogenesis, J. Musculoskel Neuron Interact 2(3):274-276 (2002).
Hemmati-Brivanlou, A., Vertebrate Neural Induction, Annual Review Neuroscience 20:43-60 (1997).
Hoppler, S., Wnt Signalling inXenopusDevelopment, http://www.personal.dundee.ac.uk/-sphopple/research.html, visited on May 1, 2002.
Itasaki, N.. et al., Wise, a context-dependent activator and inhibitor of Wnt signalling, Development 130:4295-4305.
Ivkovic, S., et al., Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development, Development 130:2779-2791 (2003).
Karsenty G., The complexities of skeletal biology, Nature 423:316-318 (2003).
Kato. M., et al., Cbfa1-Independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient inLrp5, a Wnt coreceptor, The Journal of Cell Biology, 157 (2): 303-314 (Apr. 15, 2002).
Kerszberg, M., et al., A simple molecular model of neurulation, BioEssays 20:758-770 (1998), John Wiley & Sons, Inc.
Kronenberg. H.M., et al., Developmental regulation of the growth plate, Nature 423:332-338 (2003).
Kusu, N., et al., Sclerostin is a Novel Secreted Osteoclast-Derived Bone Morphogenetic Protein (BMP) Antagonist with Unique Ligand Specificity, The American Society for Biochemistry and Molec
Ellies Debra
Krumlauf Robb
Bryan Cave LLP
Pak Michael
Stowers Institute for Medical Research
LandOfFree
Method of modulating Sost binding to LRP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of modulating Sost binding to LRP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of modulating Sost binding to LRP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729282